Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2

Pomalidomide (Pom) is an immunomodulatory drug that has efficacy against Kaposi’s sarcoma, a tumor caused by Kaposi’s sarcoma-associated herpesvirus (KSHV). Pom also induces direct cytotoxicity in primary effusion lymphoma (PEL), a B-cell malignancy caused by KSHV, in part through downregulation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrestha, Prabha, Davis, David A., Jaeger, Hannah K., Stream, Alexandra, Aisabor, Ashley I., Yarchoan, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817053/
https://www.ncbi.nlm.nih.gov/pubmed/33411730
http://dx.doi.org/10.1371/journal.ppat.1009091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817053/
https://www.ncbi.nlm.nih.gov/pubmed/33411730
http://dx.doi.org/10.1371/journal.ppat.1009091

Ejemplares similares